Evidence map›Paper›PMID 32474844›Full record

ReviewCurrent HIV/AIDS reports2020

Getting to 90-90-90: Experiences from the MaxART Early Access to ART for All (EAAA) Trial in Eswatini.

Fiona Walsh, Shaukat Khan, Till Bärnighausen, Anita Hettema, Charlotte Lejeune, Sikhathele Mazibuko, Charmaine Khudzie Mlambo, Ria Reis, Yvette Fleming, Gavin Khumalo and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current HIV/AIDS reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fiona WalshMesurado Cooperative, Cambridge, MA, USA.
Shaukat KhanClinton Health Access Initiative (CHAI), 333 Dorchester Avenue, Boston, MA, USA.
Till BärnighausenHeidelberg Institute of Global Health, University of Heidelberg, 130.3 INF, 69120, Heidelberg, Germany.
Anita HettemaClinton Health Access Initiative (CHAI), Tsekwane St, Mbabane, Eswatini.
Charlotte LejeuneClinton Health Access Initiative (CHAI), Dakar, Senegal.
Sikhathele MazibukoEswatini National ART Program (SNAP), Ministry of Health, Mbabane, Eswatini.
Charmaine Khudzie MlamboClinton Health Access Initiative (CHAI), Tsekwane St, Mbabane, Eswatini.
Ria ReisLeiden University Medical Center, Leiden University, Leiden, Netherlands.
Yvette Flemingaidsfonds, Condensatorweg 54, 1014 AX, Amsterdam, Netherlands.
Gavin KhumaloEswatini National Network of People Living with HIV (SWANNEPHA), P. O. Box 4161, Mbabane, Eswatini.
Mandisa ZwaneSAfAIDS, Lamvelase Building, Nkoseluhlaza Street, Manzini, Eswatini.
Velephi OkelloDirectorate Office, Ministry of Health, Mbabane, Eswatini.
Donna SpiegelmanDepartment of Biostatistics, Center on Methods for Implementation and Prevention Science, Yale School of Public Health, 60 College Street, New Haven, CT, 06510, USA. donna.spiegelman@yale.edu.ORCID 0000-0003-4006-4650

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe MaxART Consortium-led by the Eswatini Ministry of Health-implemented multiple interventions between 2012 and 2017 to achieve UNAIDS 90-90-90 targets. We summarize key findings from community outreach strategies in support of the first 90 goal, and from the Early Access to ART for All (EAAA) trial on the implementation of a "Treat All" strategy to achieve the second and third 90 goals within a government-managed public health system. RECENT

findingsThe MaxART Consortium demonstrated that "Fast Track," a problem-solving approach, was effective at increasing testing coverage in the community. Compared with baseline data at 3 months prior to the start of the Fast Track, there was a 273% proportional increase in HIV tests conducted among adolescent males, adolescent females, and adult men, and 722% over baseline for adolescent males. The MaxART EAAA trial further showed that implementation of the Treat All policy was associated with significant two-fold shorter time from enrollment into care to ART initiation than under the standard CD4+ cell threshold-based treatment guidelines. Finally, through the MaxART trial, Eswatini was able to identify areas for further investment, including addressing the system-side barriers to routine viral load monitoring, and designing and implementing innovative community-based approaches to reach individuals who were not more routinely accessing HIV testing and counseling services. As low- and middle-income countries adopt the Treat All approach in their national HIV care and treatment guidelines, further implementation science research is needed to understand and address the system-level barriers to achieving the benefits of Treat All for HIV-infected individuals and those at risk.

Indexed as

AdolescentAdultAnti-HIV AgentsClinical ProtocolsCommunity-Institutional RelationsCounselingEswatiniFemaleHIV InfectionsHumansMaleMass ScreeningViral LoadAnti-HIV AgentsEswatiniHIV testingRetentionSub-Saharan AfricaUniversal test and treatViral suppression

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.